Navigation Links
World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients
Date:7/19/2010

ZURICH, July 19, 2010 /PRNewswire/ -- Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.[1]

Spanning 28 countries across 4 continents and involving more than 3300 physicians, A1chieve(R) is set to be the world's largest observational study in insulin therapy.

Approximately 70 percent of the world's 285 million people with diabetes are living in these 28 emerging countries where there is a rising need and interest to look at differences in physician decisions in the management of diabetes.[2]

"Multinational observational studies like A1chieve(R) provide valuable insights in the way current therapies are applied when it comes to varying cultural, economic and epidemiological circumstances," said Philip Home, Professor of Diabetes Medicine at Newcastle University England and Chair of the A1chieve(R) Global Advisory Board.

In order to mimic the natural secretion of insulin in the body, commercially available insulin preparations are used in different ways (regimens) based on an individual's need and prevailing local practices. However it is important to evaluate these different regimens in a real life setting.

"Once completed A1chieve(R) will provide locally relevant information on the effective use of modern insulins across different regimens. This information could be further useful to inform and improve the local guidelines on the management of type 2 diabetes" added Professor Home.

Jesper H0iland, Senior Vice President, Novo Nordisk Region International Operations A/S said "The A1chieve(R) study is another major initiative demonstrating our commitment as leaders in the field of diabetes care. Our vast experience and unmatched presence in the emerging countries has enabled us to carry out such a unique and large scale research activity of clinical importance."

The results of this multinational study will be available in 2011.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit http://www.novonordisk.com.

    Further information:

    References

    1. Siddharth N. Shah, Leon Litwak, Jihad Haddad, Praful N. Chakkarwar and
    Issam Hajjaji. The A1chieve(R) study: a 60,000-person, global,
    prospective, observational study of basal, meal, and biphasic insulin
    analogs in daily clinical practice. Diabetes Research and Clinical
    Practice 88S (2010).

    2. IDF Diabetes Atlas 4th Edition, International Diabetes Federation,
    2009. http://www.diabetesatlas.org.


'/>"/>
SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Frankfurt To Host Worlds Largest Pharmaceutical Services Events In 2011
3. Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Largest Civil Settlement in Pharmaceutical Case Announced by U.S. Department of Justice
5. CyberKnife Radiosurgery Now Reimbursed Throughout France and Largest Italian Region
6. First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity
7. New York States Largest Integrated Health System Chooses Craneware Revenue Integrity Solutions
8. Russias Largest Breast Cancer Oncology Center Uses New CAD Software for Advanced Breast Cancer Detection
9. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
10. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
11. At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... York , February 5, 2016 ... Transparency Market Research report states that the global active ... 2014 and is predicted to reach US$185.9 bn by ... of 6.50% from 2014 to 2020. The title of ... Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic Area) ...
(Date:2/5/2016)... , Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and ... an agreement to acquire a majority ownership interest in ... equipment in Brazil . ... Blumenau, Brazil, Dental Cremer is the dental distribution business of ...
(Date:2/4/2016)... DUBLIN, Ohio , Feb. 4, 2016 ... Pricing Program, or those already participating in the program, ... Guidance, often referred to as the , Mega-Guidance , ... the final guidance is published in September 2016. ... 340B Product and Service Marketing , summarizes the Mega-Guidance,s ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... ranked #3 in the 2015 Best in KLAS: Software & Services for HIT ... annual Best in KLAS report independently ranks vendor performance by healthcare executives, managers ...
(Date:2/5/2016)... ... ... Stuart Bentkover, MD, FACS is thrilled to announce the arrival ... tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to offer ... been approved by the Food and Drug Administration (FDA) as a safe and efficient ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of ... A hallmark feature of patients with eating disorders is significant self-criticism, and consequently these ... and obsessions are regarded as maladaptive means for coping with this unease, but also ...
(Date:2/5/2016)... ... February 05, 2016 , ... On ... Rare Diseases, a continuing medical education (CME) event presented by the Association for ... kind—and a first for ACCORD, whose mission is to provide education, tools, and ...
(Date:2/5/2016)... ... February 05, 2016 , ... –This week, Atascadero water heater company ... tankless water heater. To view the report, click here or see below. ... each has their pros and cons, the type chosen is almost entirely up to ...
Breaking Medicine News(10 mins):